Amvuttra

Pharma

Alnylam's ATTR-CM launch blows past estimates again

Riding its March expansion into the heart condition of ATTR-CM, sales of Amvuttra again came above analysts’ consensus estimates in the third quarter.

Angus Liu Oct 30, 2025 8:00am

Pfizer to discontinue low-dose ATTR drug Vyndaqel in US in 2025

Aug 29, 2025 10:40am

Space shuttle takes off on background of blue sky

Alnylam's market cap jumps past $50B

Aug 1, 2025 7:39am

Alnylam's Amvuttra off to promising start in ATTR-CM

May 1, 2025 11:46am

Alnylam's Amvuttra wins key cardiomyopathy FDA nod

Mar 20, 2025 7:40pm

Market growth will help spark sales of Amvuttra, Alnylam says

Feb 13, 2025 2:08pm